1. MediWound reports NexoBrid® reduces traumatic tattoo formation over 90%. 2. Study demonstrates NexoBrid's effectiveness in complex trauma wound management. 3. Clinical data suggests significant advantages over traditional wound care methods. 4. Current research supports further evaluation in acute trauma settings. 5. Study published in reputable journal highlights need for larger research.
FAQ
Why Bullish?
The substantial clinical data supporting NexoBrid®’s efficacy could enhance investor confidence, similar to past successful clinical announcements that led to price increases.
How important is it?
The article presents pivotal clinical data that demonstrates NexoBrid®’s effectiveness, which is likely to influence investor sentiment and market performance significantly.
Why Long Term?
As NexoBrid® gains acceptance in clinical practices and broader awareness leads to increased sales, the long-term financial outlook is positive.
MediWound Releases Clinical Data Highlighting NexoBrid®'s Efficacy in Preventing Traumatic Tattoos
YAVNE, Israel, December 10, 2025 — MediWound Ltd. (Nasdaq: MDWD), a frontrunner in enzymatic therapeutics for tissue repair, has announced new clinical data demonstrating the effectiveness of NexoBrid® in preventing traumatic tattoos caused by abrasion and blast injuries. These findings, published in the esteemed Journal of Burn Care & Research, underscore NexoBrid®’s ability to significantly reduce embedded particles that cause permanent skin discoloration.
Understanding Traumatic Tattoos and Current Treatment Limitations
Traumatic tattoos develop when materials such as dirt, metal, or shrapnel permeate the skin during high-velocity accidents or blasts. These tattoos not only result in unsightly discoloration but also pose risks of cosmetic deformity, functional impairment, and increased possibility of infection.
Traditionally, the standard treatment for these injuries has involved aggressive mechanical scrubbing. Unfortunately, this method often fails to remove all embedded particles and can damage viable tissues.
Study Overview of NexoBrid® Effectiveness
The study involved 15 patients at Sheba Medical Center’s National Burn Center who had suffered from traumatic tattoos due to friction or blast injuries. Initially, patients received standard mechanical scrubbing to clear loose debris. Subsequently, NexoBrid® was administered within 24 hours post-injury under procedural sedation. The results were assessed using computerized image analysis, revealing striking outcomes.
- The mean pigmented wound area reduced from 37.5% to 2.1%, demonstrating a 92.5% decrease in pigmented surface area.
- In cases of abrasion injuries, an average of 96% of visible pigments were effectively removed, while explosive injuries saw an 84% reduction in pigment load.
- No adverse events related to the treatment were reported during the early post-procedure period.
Expert Insights on NexoBrid® Treatment
Professor Josef Haik, MD, MPH, Director of the Department of Plastic and Reconstructive Surgery and Burn Center at Sheba Medical Center, stated, “In blast injuries and friction burns, where wound depth is highly irregular, NexoBrid® provides the precision these cases demand. The selective enzymatic action of NexoBrid® effectively removes particles embedded within damaged skin layers, enabling clinicians to attain a clean wound bed for better treatment planning.”
Future Directions and Potential Studies
While the initial findings are promising, the study's authors acknowledge limitations, including a small sample size and short follow-up duration. They advocate for larger, controlled studies to validate the long-term cosmetic outcomes and therapeutic efficacy of NexoBrid® in complex trauma cases.
About NexoBrid® and MediWound
NexoBrid® is a topical biological orphan drug that enables the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. This innovative treatment has been approved for use in over 40 countries, including the United States, EU, and Japan, and is poised to transform wound management practices.
MediWound Ltd. (Nasdaq: MDWD) is at the vanguard of developing enzymatic, non-surgical therapies for tissue repair. Their flagship product, NexoBrid®, along with the investigational therapy EscharEx®, which targets chronic wounds, hold great potential to set new standards in wound care.